The low level of Hb, in general, is indicative of a subclinical anemia status that has been frequently reported as a poor prognosis biomarker for mSTS as well as in other tumor types (Szkandera et al., 2014; Shi et al., 2021). This evidence concerns the gene GSTM1 and anemia.